A Clinical Study of CD19 CAR NK Cells for the Treatment of Relapsed/Refractory B-cell Related Autoimmune Diseases
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: anti-CD19 CAR NK cells.
- Who it may be relevant to
- Registry conditions: Autoimmune Diseases. Basic parameters: 18 years — 70 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
An Exploratory Clinical Study of the Safety and Efficacy of CD19 Chimeric Antigen Receptor NK Cell Injections for the Treatment of Relapsed/Refractory B-cell Related Autoimmune Diseases
Overview
A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-CD19 CAR NK cells (KN5501) in patients with relapsed/refractory B-cell related autoimmune diseases.15 patients are planned to be enrolled in the dose-escalation trial (6×10\^9 cells, 9×10\^9 cells). The primary objective of the study is to evaluation of the safety and feasibility of KN5501 for the treatment of relapsed/refractory B-cell related autoimmune diseases. The secondary objective is to evaluate the effectiveness of KN5501 for the treatment of relapsed/refractory B-cell related autoimmune diseases. The exploratory objective is to evaluate expansion, persistence and ability to deplete CD19 positive B cells of KN5501 in patients with relapsed/refractory B-cell related autoimmune diseases.
Interventions
- Drug anti-CD19 CAR NK cells
Patients will receive Fludarabine (30mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3, followed by Anti-CD19 CAR NK cells infusion.
Primary outcome measures
- Incidence of Dose Limiting Toxicity (DLTs) [Time frame: within 4 weeks after infusion; 12, 24, 36 and 52 weeks after infusion]
- Treatment Emergent Adverse Events（TEAEs） [Time frame: within 4 weeks after infusion; 12, 24, 36 and 52 weeks after infusion]
Secondary outcome measures (2)
- Disease control rate of subjects [Time frame: 4, 12, 24, and 52 weeks after infusion]
- Remission rate of subjects [Time frame: 4, 12, 24, and 52 weeks after infusion]
Eligibility criteria
Inclusion criteria
- Subjects voluntarily participate in this clinical study and sign the Informed Consent Form (ICF) and are willing to follow and be able to complete all trial procedures
- Subjects disease status of enrolment: not complete response (CR) after standard treatment; moderately to severely active autoimmune diseases
- Age: ≥ 18 years old and ≤ 70 years old, male or female
- Subjects with estimated survival > 12 weeks
- Adequate organs function: Serum creatinine clearance meets relevant age/sex criteria,aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 times the upper limit of normal (ULN)
- ECOG performance ≤ 2
- Left ventricular ejection fraction (LVEF) ≥ 45%
- Subjects have been treated with OCS in combination with an immunosuppressive or biologic agent for at least 2 weeks prior to enrollment
Exclusion criteria
- Subjects with known severe allergic reactions, hypersensitivity, contraindication to any medications during the trial (cyclophosphamide, fludarabine, tozumabs), or subjects with a history of severe allergic reactions
- Subjects with one of the following genetic syndromes: Fanconi syndrome, Kostmann syndrome, Shwachman syndrome or any of the known bone marrow failure syndromes
- Subjects with active or uncontrolled infections requiring parenteral antimicrobials; evidence of severe active viral or bacterial infections or uncontrolled systemic fungal infections
- Subjects with grade III or IV heart failure (NYHA classification)
- History of epilepsy or other central nervous system (CNS) diseases
- History of other primary malignant tumors except: cured non-melanoma skin cancer or primary cervical cancer; subjects with inactive tumors
- Subjects with more pronounced bleeding tendencies, such as gastrointestinal bleeding, coagulation disorders, and hypersplenism
- Subjects were treated with systemic corticosteroids concomitantly within 2 weeks prior to treatment
- Subjects with unstable angina, symptomatic congestive heart failure or myocardial infarction within the last 6 months
- Females who are pregnant, lactating, or planning a pregnancy within six months
- Subjects who have received other clinical trial treatment within 3 months
- Any situation judged by the investigators that may increase the risk of the subjects or interfere with the clinical trial outcome
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
China · 2 centers
- Affiliated Hospital of Jiangsu University — Zhenjiang
- Jiangsu University Affiliated Hospital — Zhenjiang
Identifiers
NCT: NCT06318533 · 2023-11-01